Alan raises €480m from Prosus, hits €5.5bn valuation just months after last round

Alan has raised €480m in a round led by Dutch investor Prosus, pushing its valuation to €5.5bn. The Paris-based health insurer closed the deal only three months after taking in €100m at a €5bn valuation, an unusually fast sequence of raises for a European company its size.

Dara Holdings, a British fund, joined as a new backer, alongside existing investors Teachers' Venture Growth and Index Ventures. The new round takes Alan's total funding past €1.2bn and ranks among the largest non-AI financings in Europe this year.

Why raise again so soon

Alan has not said in detail what the €480m will fund, which is notable given that its finance chief, Mihaela Albu, said in March the company already held ample cash. At the time, she pointed to acquisitions and international expansion as priorities. Those remain the themes now: Alan operates in France, Belgium and Spain, has recently moved into Canada, where it won a sizeable contract, and intends to enter another country by 2027.

Founder and chief executive Jean-Charles Samuelian-Werve framed the Prosus deal as a way to move faster rather than simply raise more cash for its own sake. He said the financing gives Alan the means to pursue its ambition "at an unprecedented scale" and welcomed Prosus's experience taking technology companies global.

Prosus, the investment arm tied to Naspers and its Tencent stake, has a history of buying into consumer platforms, including Just Eat Takeaway and Stack Overflow. Alan is betting that network can help it break into markets where it currently has no presence.

Profitable at home, still losing money as a group

The business has grown quickly. Annual recurring revenue reached roughly €787m in the first quarter of 2026, up more than half on the year before. The company counts over 1.1 million members and more than 37,000 corporate and public-sector clients, including Kiabi, Veepee, Intersport and Etam.

It has also picked up public contracts, among them a deal with France's Ministry of Economy and Finance covering more than 130,000 civil servants, plus work with the Cour des comptes and the civil aviation authority. Those wins matter because public tenders have traditionally gone to incumbent insurers rather than newer entrants.

Despite that growth, Alan posted a €26m loss at group level last year. France, which makes up more than three-quarters of its business, turned profitable in 2025 for the first time, and the company says it is targeting profitability across the whole group by 2027. Management has chosen to keep spending on product and expansion rather than force an earlier break-even.

Betting beyond insurance

The company increasingly positions itself as more than an insurer. Over the past two years it has added Shop, a wellness and health products marketplace, Walk, a step-counting feature, and Mo, an AI health assistant, all built into its app alongside its virtual clinic.

Samuelian-Werve has said he wants Alan to become what he calls the first integrated health system in which prevention itself generates profit, rather than treating prevention as a side feature bolted onto an insurance policy. That framing, sometimes described externally as "prevention insurance," is central to how the company pitches itself to investors now.

The approach fits a broader pattern in European health-tech, where companies such as Neko Health, the body-scanning startup backed by Spotify's Daniel Ek, are also chasing early detection and prevention rather than treatment after the fact. Whether any of them can turn that pitch into durable margins at scale is still unproven.

What comes next

Alan marked its tenth anniversary a few weeks before the round closed, with footballer Kylian Mbappé appearing on stage as a newly signed brand ambassador, a sign of how far the company has moved from its original niche as a digital health insurer for French startups.

The round still needs regulatory clearance, since Alan operates as a licensed insurer under France's ACPR rather than as a broker, a step that pure software companies do not face. For a French tech sector that saw overall funding slip in 2025, a deal of this size is a rare bright spot. The open question is whether Alan can convert its rapid fundraising pace and international ambitions into profitable growth across all four of its markets by its self-imposed 2027 deadline.